Intensity Therapeutics (INTZ) Stock Up 8% on New Autoimmune Treatment Data

INTZ shares surged 8% on February 9, 2026, after the company released positive preliminary results for its lead autoimmune treatment candidate, INT-801, in a Phase 2 trial. The trial showed a 40% reduction in disease activity scores and a 30% improvement in patient-reported outcomes. The data, presented at a major medical conference, support the company’s plan to file a Biologics License Application in the second half of 2026. INTZ is scheduled to release detailed results in a press release on February 15, 2026.